BioRestorative Therapies(BRTX) - 2023 Q2 - Quarterly Report

Results of Operations Revenues We expect that our research and development expenses will increase in subsequent fiscal periods. For the three months ended June 30, 2023, interest income was $96,187 compared to interest expense of $46,613 for the three months ended June 30, 2022. The change was primarily due to our investments in marketable securities during the three months ended 18 Revenues We expect that our higher level of research and development expenses will continue in subsequent fiscal periods. Inte ...